"Who should receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when?"

Area of Science:

• Oncology
• Pharmacology
• Genetics

Background:

• Epidermal growth factor receptor (EGFR) pathway inhibition is a key strategy in non-small cell lung cancer (NSCLC) treatment.
• Erlotinib and gefitinib are EGFR tyrosine kinase inhibitors (TKIs) with demonstrated activity in advanced NSCLC.
• Previous trials suggest differential efficacy in specific patient subsets.

Purpose of the Study:

• To review the efficacy of EGFR TKIs in advanced NSCLC.
• To identify patient and tumor characteristics predictive of response to EGFR TKI therapy.
• To inform clinical decision-making regarding the use of erlotinib and gefitinib.

Main Methods:

• Analysis of subset data from Phase II and Phase III clinical trials.
• Review of clinical outcomes including survival, response rates, and quality of life.
• Consideration of patient demographics (e.g., smoking status, ethnicity) and tumor molecular markers (e.g., EGFR FISH/mutation status, KRAS mutation status).

Main Results:

• Never smokers showed statistically significant survival improvements with erlotinib or gefitinib.
• Patients with EGFR FISH-positive or mutation-positive tumors exhibited improved response rates to TKIs.
• Tumors with KRAS mutations did not benefit from TKI therapy; erlotinib improved survival and quality of life in the BR.21 trial.

Conclusions:

• EGFR TKI therapy, particularly erlotinib, is a viable option for second- or third-line treatment in advanced NSCLC.
• While specific predictive markers are still under investigation, never smokers and patients with EGFR mutations represent key subsets.
• Ongoing prospective trials aim to further elucidate patient and tumor characteristics that predict clinical benefit from TKI therapy.